PRIME MEDICINE INC (PRME) Stock Price, Quote, News and Overview
NASDAQ:PRME - Nasdaq - US74168J1016 - Common Stock - Currency: USD
PRME Quote, Performance and Key Statistics
1.69
-0.06 (-3.43%)
The current stock price of PRME is 1.69 USD. In the past month the price decreased by -15.5%. In the past year, price decreased by -61.81%.
PRME Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.31B |
Related stock screener links
About PRME
Company Profile
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2022-10-20. The company deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. The company is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. The company has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.
Company Info
PRIME MEDICINE INC
60 First St.
Cambridge MASSACHUSETTS US
Employees: 234
Company Website: https://primemedicine.com/
Investor Relations: https://investors.primemedicine.com/
Phone: 16174650013
PRIME MEDICINE INC / PRME FAQ
What is the stock price of PRIME MEDICINE INC today?
The current stock price of PRME is 1.69 USD. The price decreased by -3.43% in the last trading session.
What is the ticker symbol for PRIME MEDICINE INC stock?
The exchange symbol of PRIME MEDICINE INC is PRME and it is listed on the Nasdaq exchange.
On which exchange is PRME stock listed?
PRME stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRIME MEDICINE INC stock?
18 analysts have analysed PRME and the average price target is 14.17 USD. This implies a price increase of 738.27% is expected in the next year compared to the current price of 1.69. Check the PRIME MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRIME MEDICINE INC worth?
PRIME MEDICINE INC (PRME) has a market capitalization of 221.66M USD. This makes PRME a Micro Cap stock.
How many employees does PRIME MEDICINE INC have?
PRIME MEDICINE INC (PRME) currently has 234 employees.
What are the support and resistance levels for PRIME MEDICINE INC (PRME) stock?
PRIME MEDICINE INC (PRME) has a resistance level at 1.79. Check the full technical report for a detailed analysis of PRME support and resistance levels.
Is PRIME MEDICINE INC (PRME) expected to grow?
The Revenue of PRIME MEDICINE INC (PRME) is expected to grow by 393.94% in the next year. Check the estimates tab for more information on the PRME EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRIME MEDICINE INC (PRME) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRME, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRME, evaluating the profitability, health, valuation and growth aspects
- PRIME MEDICINE INC (PRME) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRIME MEDICINE INC (PRME) Sales and EPS estimates to see what analysts future expectations are.
- PRIME MEDICINE INC (PRME) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRIME MEDICINE INC (PRME) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRIME MEDICINE INC (PRME) Stock Chart to make your own analysis
- PRIME MEDICINE INC (PRME) Latest news and press-releases to stay up to date.
Does PRIME MEDICINE INC (PRME) stock pay dividends?
PRME does not pay a dividend.
When does PRIME MEDICINE INC (PRME) report earnings?
PRIME MEDICINE INC (PRME) will report earnings on 2025-05-09.
What is the Price/Earnings (PE) ratio of PRIME MEDICINE INC (PRME)?
PRIME MEDICINE INC (PRME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of PRIME MEDICINE INC (PRME) stock?
The outstanding short interest for PRIME MEDICINE INC (PRME) is 19.44% of its float. Check the ownership tab for more information on the PRME short interest.
PRME Technical Analysis
PRME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRME. While PRME has a great health rating, there are worries on its profitability.
PRME Financial Highlights
Over the last trailing twelve months PRME reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 24.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.84% | ||
| ROE | -127.9% | ||
| Debt/Equity | 0 |
PRME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PRME. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 24.65% and a revenue growth 393.94% for PRME